Lupus nephritis: Current update

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Saxena, Ramesh ^a   Mahajan, Tina ^a   Mohan, Chandra ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ALPHA INTERFERON; AZATHIOPRINE; B7 ANTIGEN; BELIMUMAB; CD11B ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; CREATININE; CYCLOPHOSPHAMIDE; EPRATUZUMAB; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; METHYLPREDNISOLONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OX40 LIGAND; PREDNISONE; RANTES; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; AUTACOID;

AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL FEATURE; CYTOKINE PRODUCTION; FOLLOW UP; GLOMERULONEPHRITIS; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY FAILURE; LEUKOCYTURIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; PATHOGENESIS; PROTEIN URINE LEVEL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; PHYSIOLOGY;

ANIMALS; CYCLOPHOSPHAMIDE; HUMANS; INFLAMMATION MEDIATORS; LUPUS NEPHRITIS;

EID: 81255196460     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3378     Document Type: Review

References (143)

1. Appel GB, Radhakrishnan J, D'Agati V. Secondary glomerular disease. The Kidney 2007, 1067-1148. Philadelphia, PA: Saunders, Brenner BM, 8.
2. Bertsias G, Gordon C, Boumpas DT. Clinical trials in SLE: lessons learned from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus 2008, 17:437-442. 10.1177/0961203308090031, 18490423.
3. Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC. Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 2007, 16:28-34. 10.1177/0961203306074469, 17283582.
4. Seligman VA, Lum RF, Olson JL, Li H, Criswell LA. Demographic differences in the outcome of SLE nephritis: a retrospective analysis. Am J Med 2002, 112:726-729. 10.1016/S0002-9343(02)01118-X, 12079714.
5. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999, 10:413-424.
6. Austin HA. Clinical evaluation and monitoring of systemic lupus erythematosis. Lupus 1998, 7:618-621. 10.1191/096120398678920749, 9884099.
7. McCluskey RT. Lupus nephritis. Kidney Pathology Decennial 1966-1975 1975, 435-450. East Norwalk, CT: Appleton-Century Crofts, Sommers SC.
8. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984, 25:689-695. 10.1038/ki.1984.75, 6482173.
9. Weening JJ, D'Agati VD, Schwartz MM. The classification of glomerulonephritis in systemic lupus erythematosis revisited. J Am Soc Nephrol 2004, 15:241-250. 10.1097/01.ASN.0000108969.21691.5D, 14747370.
10. Furness PN, Taub N. Interobserver reproducibility and application of the INS/RPS classification of lupus nephritis - a UK-wide study. Am J Surg Pathol 2006, 30:1030-1035. 10.1097/00000478-200608000-00015, 16861976.
11. Yokoyama H, Wada T, Hara A, Yamahana J, Nakaya I, Kobayashi M, Kokubo KS, Iwata Y, Yoshimoto K, Shimizu K, Sakai N, Furuichi KT. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004, 66:2382-2388. 10.1111/j.1523-1755.2004.66027.x, 15569330.
12. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006, 18:468-475.
13. Kanta H, Mohan C. Murine lupus genes target 3 checkpoints in disease development - central tolerance in the adaptive immune system, peripheral amplification by innate immunity, and end-organ inflammation. Genes Immun 2009, 10:390-396. 10.1038/gene.2009.6, 19262576.
14. Hahn BH. Antibodies to DNA. N Engl J Med 1998, 338:1359-1368. 10.1056/NEJM199805073381906, 9571257.
15. D'Agati VD, Appel GB, Estes D, Knowles DM, Pirani CL. Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int 1986, 30:573-581. 10.1038/ki.1986.223, 3537453.
16. Díaz Gallo C, Jevnikar AM, Brennan DC, Florquin S, Pacheco-Silva A, Kelley VR. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int 1992, 42:851-859. 10.1038/ki.1992.360, 1360551.
17. Mukherjee R, Zhang Z, Zhong R, Yin ZQ, Roopenian DC, Jevnikar AM. Lupus nephritis in the absence of renal major histocompatibility complex class I and class II molecules. J Am Soc Nephrol 1996, 7:2445-2452.
18. Koh DR, Ho A, Rahemtulla A, Fung-Leung WP, Griesser H, Mak TW. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 1995, 25:2558-2562. 10.1002/eji.1830250923, 7589126.
19. Jabs DA, Burek CL, Hu Q, Kuppers RC, Lee B, Prendergast RA. Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice. Cell Immunol 1992, 141:496-507. 10.1016/0008-8749(92)90166-M, 1576659.
20. Jabs DA, Kuppers RC, Saboori AM, Burek CL, Enger C, Lee B, Prendergast RA. Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice. Cell Immunol 1994, 154:66-76. 10.1006/cimm.1994.1057, 7907009.
21. Radeke HH, Tschernig T, Karulin A, Schumm G, Emancipator SN, Resch K, Tary-Lehmann M. CD4+ T cells recognizing specific antigen deposited in glomeruli cause glomerulonephritis-like kidney injury. Clin Immunol 2002, 104:161-173. 10.1006/clim.2002.5246, 12165277.
22. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996, 97:2063-2073. 10.1172/JCI118643, 507281, 8621796.
23. Koshy M, Berge D, Crow MK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98:826-837. 10.1172/JCI118855, 507493, 8698875.
24. Devi BS, Van Noordin S, Krausz T, Davies KA. Peripheral blood lymphocytes in SLE - hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 1998, 11:471-475. 10.1006/jaut.1998.0213, 9802931.
25. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998, 160:2158-2165.
26. Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, Davidson A. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum 2003, 48:495-506. 10.1002/art.10929, 12571860.
27. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993, 178:669-674. 10.1084/jem.178.2.669, 2191134, 7688031.
28. Caux C, Massacrier C, Vanbervliet B, Dubois B, van Kooten C, Durand I, Banchereau J. Activation of human dendritic cells through CD40 crosslinking. J Exp Med 1994, 180:1263-1272. 10.1084/jem.180.4.1263, 2191669, 7523569.
29. Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D, Estes D, Szabolcs M, Chess L. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997, 40:124-134. 10.1002/art.1780400117, 9008608.
30. Kuroiwa T, Schlimgen R, Illei GG, McInnes IB, Boumpas DT. Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. J Immunol 2000, 164:3323-3329.
31. van Kooten C, Gerritsma JS, Paape ME, van Es LA, Banchereau J, Daha MR. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997, 51:711-721. 10.1038/ki.1997.102, 9067903.
32. Uhm WS, Na K, Song GW, Jung SS, Lee T, Park MH, Yoo DH. Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) 2003, 42:935-938.
33. Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol 2004, 138:171-178. 10.1111/j.1365-2249.2004.02588.x, 1809179, 15373921.
34. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, Fukuda K, Kanai H, Nakashima H, Otsuka T, Hirakata H. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001, 44:2097-2106. 10.1002/1529-0131(200109)44:9<2097::AID-ART360>3.0.CO;2-6, 11592372.
35. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol 2008, 154:247-254. 10.1111/j.1365-2249.2008.03758.x, 2612719, 18795942.
36. Chan RW, Tam LS, Li EK, Lai FM, Chow KM, Lai KB, Li PK, Szeto CC. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003, 48:1326-1331. 10.1002/art.11062, 12746905.
37. Jacob CO, van der Meide PH, McDevitt HO. In vivo treatment of (NZB × NZW) F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987, 166:798-803. 10.1084/jem.166.3.798, 2188698, 3114409.
38. Peng SL, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest 1997, 99:1936-1946. 10.1172/JCI119361, 508018, 9109438.
39. Balomenos D, Rumold R, Theoilopoulos AN. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998, 101:364-371. 10.1172/JCI750, 508575, 9435308.
40. Bossù P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, Fantuzzi G, Dinarello CA, Di Carlo E, Musiani P, Meroni PL, Caselli G, Ruggiero P, Boraschi D. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci USA 2003, 100:14181-14816. 10.1073/pnas.2336094100, 283566, 14615579.
41. Nakajima A, Hirose S, Yagita H, Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 1997, 158:1466-1472.
42. Rüger BM, Erb KJ, He Y, Lane JM, Davis PF, Hasan Q. Interleukin-4 transgenic mice develop glomerulosclerosis independent of immunoglobulin deposition. Eur J Immunol 2000, 30:2698-2703. 10.1002/1521-4141(200009)30:9<2698::AID-IMMU2698>3.0.CO;2-1, 11009105.
43. Singh RR, Saxena V, Zang S, Li L, Finkelman FD, Witte DP, Jacob CO. Differential contribution of IL-4 and STAT6 vs. STAT4 to the development of lupus nephritis. J Immunol 2003, 170:4818-4825. 2291553, 12707364.
44. Singh RR. IL-4 and many roads to lupuslike autoimmunity. Clin Immunol 2003, 108:73-79. 10.1016/S1521-6616(03)00145-1, 12921752.
45. Woltman AM, de Fijter JW, Zuidwijk K, Vlug AG, Bajema IM, van der Kooij SW, van Ham V, van Kooten C. Quantification of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int 2007, 71:1001-1008. 10.1038/sj.ki.5002187, 17361115.
46. Krüger T, Benke D, Eitner F, Lang A, Wirtz M, Hamilton-Williams EE, Engel D, Giese B, Müller-Newen G, Floege J, Kurts C. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J Am Soc Nephrol 2004, 15:613-621. 10.1097/01.ASN.0000114553.36258.91, 14978163.
47. Soos TJ, Sims TN, Barisoni L, Lin K, Littman DR, Dustin ML, Nelson PJ. CX(3) CR1(+) interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 2006, 70:591-596.
48. Fiore N, Castellano G, Blasi A, Capobianco C, Loverre A, Montinaro V, Netti S, Torres D, Manno C, Grandaliano G, Ranieri E, Schena FP, Gesualdo L. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol 2008, 45:259-265. 10.1016/j.molimm.2007.04.029, 17570528.
49. Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum 2008, 58:251-262. 10.1002/art.23186, 18163476.
50. Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, Rönnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. J Autoimmun 1998, 11:465-470. 10.1006/jaut.1998.0215, 9802930.
51. Gill MA, Blanco P, Arce E, Pascual V, Banchereau J, Palucka AK. Blood dendritic cells and DC-poietins in systemic lupus erythematosus. Hum Immunol 2002, 63:1172-1180. 10.1016/S0198-8859(02)00756-5, 12480261.
52. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001, 159:237-243. 10.1016/S0002-9440(10)61689-6, 1850412, 11438470.
53. Bagavant H, Deshmukh US, Wang H, Ly T, Fu SM. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J Immunol 2006, 177:8258-8265.
54. Schiffer L, Bethunaickan R, Ramanujam M, Huang W, Schiffer M, Tao H, Madaio MP, Bottinger EP, Davidson A. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008, 180:1938-1947. 2587994, 18209092.
55. Fujinaka H, Nameta M, Kovalenko P, Matsuki A, Kato N, Nishimoto G, Yoshida Y, Yaoita E, Naito M, Kihara I, Tomizawa S, Yamamoto T. Periglomerular accumulation of dendritic cells in rat crescentic glomerulonephritis. J Nephrol 2007, 20:357-363.
56. Scholz J, Lukacs-Kornek V, Engel DR, Specht S, Kiss E, Eitner F, Floege J, Groene HJ, Kurts C. Renal dendritic cells stimulate IL-10 production and attenuate nephrotoxic nephritis. J Am Soc Nephrol 2008, 19:527-537. 10.1681/ASN.2007060684, 2391058, 18235094.
57. Monrad S, Kaplan MJ. Dendritic cells and the immunopathogenesis of systemic lupus erythematosus. Immunol Res 2007, 37:135-145. 10.1007/BF02685895, 17695248.
58. Coates PT, Colvin BL, Ranganathan A, Duncan FJ, Lan YY, Shufesky WJ, Zahorchak AF, Morelli AE, Thomson AW. CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilization. Kidney Int 2004, 66:1907-1917. 10.1111/j.1523-1755.2004.00965.x, 15496162.
59. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895. 10.1038/nature04651, 16612374.
60. Tucci M, Calvani N, Richards HB, Quatraro C, Silvestris F. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci 2005, 1051:421-432. 10.1196/annals.1361.084, 16126984.
61. Hooke DH, Gee DC, Atkins RC. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int 1987, 31:964-972. 10.1038/ki.1987.93, 3495689.
62. Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990, 37:100-109. 10.1038/ki.1990.14, 1967662.
63. Kootstra CJ, Sutmuller M, Baelde HJ, de Heer E, Bruijn JA. Association between leukocyte infiltration and development of glomerulosclerosis in experimental lupus nephritis. J Pathol 1998, 184:219-225. 10.1002/(SICI)1096-9896(199802)184:2<219::AID-PATH990>3.0.CO;2-9, 9602715.
64. Lan HY, Nikolic-Paterson DJ, Mu W, Atkins RC. Local macrophage proliferation in the pathogenesis of glomerular crescent formation in rat anti-glomerular basement membrane (GBM) glomerulonephritis. Clin Exp Immunol 1997, 110:233-240. 2265489, 9367407.
65. Holdsworth SR, Neale TJ, Wilson CB. Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest 1981, 68:686-698. 10.1172/JCI110304, 370850, 7276168.
66. Duffield JS, Tipping PG, Kipari T, Cailhier JF, Clay S, Lang R, Bonventre JV, Hughes J. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005, 167:1207-1219. 10.1016/S0002-9440(10)61209-6, 1603796, 16251406.
67. Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ. Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 2003, 63:83-95.
68. Holdsworth SR, Neale TJ. Macrophage-induced glomerular injury. Cell transfer studies in passive autologous antiglomerular basement membrane antibody-initiated experimental glomerulonephritis. Lab Invest 1984, 51:172-180.
69. Tipping PG, Timoshanko J. Contributions of intrinsic renal cells to crescentic glomerulonephritis. Nephron Exp Nephrol 2005, 101:e173-e178. 10.1159/000088165, 16155400.
70. Timoshanko JR, Tipping PG. Resident kidney cells and their involvement in glomerulonephritis. Curr Drug Targets Inflamm Allergy 2005, 4:353-362. 10.2174/1568010054022132, 16101545.
71. Li S, Kurts C, Kontgen F, Holdsworth SR, Tipping PG. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med 1998, 188:597-602. 10.1084/jem.188.3.597, 2212465, 9687536.
72. Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, Putterman C. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett 2009, 125:119-128. 10.1016/j.imlet.2009.06.010, 19573558.
73. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J Am Soc Nephrol 2003, 14:1785-1793. 10.1097/01.ASN.0000073902.38428.33, 12819238.
74. Ka SM, Cheng CW, Shui HA, Wu WM, Chang DM, Lin YC, Chen A. Mesangial cells of lupus-prone mice are sensitive to chemokine production. Arthritis Res Ther 2007, 9:R67. 10.1186/ar2226, 2206365, 17617918.
75. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J Immunol 2000, 164:1498-1504.
76. Reilly CM, Oates JC, Sudian J, Crosby MB, Halushka PV, Gilkeson GS. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol 2001, 98:337-345. 10.1006/clim.2000.4985, 11237557.
77. Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008, 181:8761-8766. 2596652, 19050297.
78. Kang HK, Liu M, Datta SK. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells. J Immunol 2007, 178:7849-7858.
79. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 10.1084/jem.20021553, 2193846, 12642603.
80. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 10.1073/pnas.0337679100, 151388, 12604793.
81. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG, Ly N, Woodward RN, Fry KE, Lau AY, Prentice JG, Wohlgemuth JG, Crow MK. Coordinate overexpression of interferon-alpha induced genes in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3958-3967. 10.1002/art.20798, 15593221.
82. Fairhurst AM, Xie C, Fu YY, Wang A, Boudreaux CD, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 2009, 183:6831-6838. 10.4049/jimmunol.0900742, 2876821, 19864599.
83. Border WA, Ruoslahti E. Transforming growth factor beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90:1-7. 10.1172/JCI115821, 443055, 1634602.
84. Nakamura T, Ebihara I, Shirato I, Tomino Y, Koide H. Increased steady-state levels of mRNA coding for extracellular matrix components in kidneys of NZB/W F1 mice. Am J Pathol 1991, 139:437-450. 1886086, 1867327.
85. Nakamura T, Ebihara I, Nagaoka I, Osada S, Tomino Y, Koide H. Effect of methylprednisolone on transforming growth factor-beta, insulin-like growth factor-I, and basic fibroblast growth factor gene expression in the kidneys of NZB/W F1 mice. Ren Physiol Biochem 1993, 16:105-116.
86. Taniguchi Y, Yorioka N, Masaki T, Yamashita K, Ito T, Ueda H, Yamakido M. Role of transforming growth factor-beta 1 in glomerulonephritis. J Int Med Res 1997, 25:71-80.
87. Saxena V, Lienesch DW, Zhou M, Bommireddy R, Azhar M, Doetschman T, Singh RR. Dual roles of immunoregulatory cytokine TGF-β in the pathogenesis of autoimmunity-mediated organ damage. J Immunol 2008, 180:1903-1912. 2291535, 18209088.
88. Bloom RD, Florquin S, Singer GG, Brennan DC, Kelley VR. Colony stimulating factor-1 in the induction of lupus nephritis. Kidney Int 1993, 143:1000-1009.
89. Isbel NM, Hill PA, Foti R, Mu W, Hurst LA, Stambe C, Lan HY, Atkins RC, Nikolic-Paterson DJ. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001, 60:614-625. 10.1046/j.1523-1755.2001.060002614.x, 11473644.
90. Yui MA, Brissette WH, Brennan DC, Wuthrich RP, Rubin-Kelley VE. Increased macrophage colony-stimulating factor in neonatal and adult autoimmune MRL-lpr mice. Am J Pathol 1991, 139:255-261. 1886069, 1867317.
91. Naito T, Yokoyama H, Moore KJ, Dranoff G, Mulligan RC, Kelley VR. Macrophage growth factors introduced into the kidney initiate renal injury. Mol Med 1996, 2:297-312. 2230158, 8784783.
92. Lan HY, Yang N, Nikolic-Paterson DJ, Yu XQ, Mu W, Isbel NM, Metz CN, Bucala R, Atkins RC. Expression of macrophage migration inhibitory factor in human glomerulonephritis. Kidney Int 2000, 57:499-509. 10.1046/j.1523-1755.2000.00869.x, 10652026.
93. Lan HY, Mu W, Yang N, Meinhardt A, Nikolic-Paterson DJ, Ng YY, Bacher M, Atkins RC, Bucala R. De novo renal expression of macrophage migration inhibitory factor during the development of rat crescentic glomerulonephritis. Am J Pathol 1996, 149:1119-1127. 1865205, 8863661.
94. Otukesh H, Chalian M, Hoseini R, Chalian H, Hooman N, Bedayat A, Yazdi RS, Sabaghi S, Mahdavi S. Urine macrophage migration inhibitory factor in pediatric systemic lupus erythematosus. Clin Rheumatol 2007, 26:2105-2107. 10.1007/s10067-007-0632-z, 17479310.
95. Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, James WG, Kitching AR, Morand EF. Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006, 177:5687-5696.
96. Sasaki S, Nishihira J, Ishibashi T, Yamasaki Y, Obikane K, Echigoya M, Sado Y, Ninomiya Y, Kobayashi K. Transgene of MIF induces podocyte injury and progressive mesangial sclerosis in the mouse kidney. Kidney Int 2004, 65:469-481. 10.1111/j.1523-1755.2004.00394.x, 14717917.
97. Yang N, Nikolic-Patersonm DJ, Ng YY, Mu W, Metz C, Bacher M, Meinhardt A, Bucala R, Atkins RC, Lan HY. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998, 4:413-424. 2230272, 10780884.
98. Lan HY, Bacher M, Yang N, Mu W, Nikolic-Paterson DJ, Metz C, Meinhardt A, Bucala R, Atkins RC. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997, 185:1455-1465. 10.1084/jem.185.8.1455, 2196273, 9126926.
99. Fu Y, Du Y, Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin Immunol 2007, 124:109-118. 10.1016/j.clim.2007.05.007, 17640604.
100. Zoja C, Liu XH, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G. Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 1997, 8:720-729.
101. Pérez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, Schlöndorff D. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001, 12:1369-1382.
102. Marks SD, Williams SJ, Tullus K, Sebire NJ. Glomerular expression of monocyte chemoattractant protein-1 is predictive of poor renal prognosis in pediatric lupus nephritis. Nephrol Dial Transplant 2008, 23:3521-3526. 10.1093/ndt/gfn270, 18495743.
103. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Lai KB, Li PK, Szeto CC. Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 2007, 66:886-892. 10.1136/ard.2006.063123, 1955122, 17324967.
104. Noris M, Bernasconi S, Casiraghi F, Sozzani S, Gotti E, Remuzzi G, Mantovani A. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 1995, 73:804-809.
105. Wada T, Yokoyama H, Su SB, Mukaida N, Iwano M, Dohi K, Takahashi Y, Sasaki T, Furuichi K, Segawa C, Hisada Y, Ohta S, Takasawa K, Kobayashi K, Matsushima K. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996, 49:761-767. 10.1038/ki.1996.105, 8648917.
106. Lu B, Rutledge BJ, Gu L, Fiorillo J, Lukacs NW, Kunkel SL, North R, Gerard C, Rollins BJ. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998, 187:601-608. 10.1084/jem.187.4.601, 2212142, 9463410.
107. Hasegawa H, Kohno M, Sasaki M, Inoue A, Ito MR, Terada M, Hieshima K, Maruyama H, Miyazaki J, Yoshie O, Nose M, Fujita S. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003, 48:2555-2566. 10.1002/art.11231, 13130475.
108. Shimizu S, Nakashima H, Masutani K, Inoue Y, Miyake K, Akahoshi M, Tanaka Y, Egashira K, Hirakata H, Otsuka T, Harada M. Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice. Rheumatology (Oxford) 2004, 43:1121-1128.
109. Shimizu S, Nakashima H, Karube K, Ohshima K, Egashira K. Monocyte chemoattractant protein-1 activates a regional Th1 immunoresponse in nephritis of MRL/lpr mice. Clin Exp Rheumatol 2005, 23:239-242.
110. Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlöndorff D. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004, 15:1504-1513. 10.1097/01.ASN.0000130082.67775.60, 15153561.
111. Chong BF, Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opin Ther Targets 2009, 13:1147-1153. 10.1517/14728220903196761, 19670960.
112. Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, Igarashi P, Zhou XJ, Batteux F, Wong D, Wakeland EK, Mohan C. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J Immunol 2009, 182:4448-4458. 10.4049/jimmunol.0801920, 2946082, 19299746.
113. Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A, Baleux F, Portier A, Durand-Gasselin I, Coffman RL, Galanaud P, Peuchmaur M, Emilie D. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J Immunol 2003, 170:3392-3400.
114. Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosis. J Lab Clin Med 1964, 63:537-550.
115. Fiehn C, Hajjar Y, Mueller K. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003, 62:435-439. 10.1136/ard.62.5.435, 1754523, 12695156.
116. Austin HA, Boumpas DT, Vaughan EM, Balow JE. Highrisk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995, 10:1620-1628.
117. Lupus nephritis: prognostic factors and probability of maintaining lifesupporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL). Am J Kidney Dis 1992, 19:473-479.
118. Austin HA, Kilppel JH, Balow JE. Therapy of lupus nephritis. Controlled trail of prednisone and cytotoxic drugs. N Engl J Med 1986, 10:614-619.
119. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann Int Med 1996, 125:549-557.
120. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999, 92:211-218. 10.1093/qjmed/92.4.211, 10396609.
121. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131. 10.1002/art.10461, 12209517.
122. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85-118. 10.1016/S0162-3109(00)00188-0, 10878285.
123. Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Lau CS, Wong AKM, Tong MKL, Chan KW, Lai KN. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000, 343:1156-1162. 10.1056/NEJM200010193431604, 11036121.
124. Ginzler EM, Dooley MA, Aranow C. Mycophenolate mofetil or IV cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228. 10.1056/NEJMoa043731, 16306519.
125. Appel GB, Contreras G, Dooley MA. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1116. 10.1681/ASN.2008101028, 2678035, 19369404.
126. Contreras H, Sosnov J. Role of mycophenolate mofetil in the treatment of lupus nephritis. Clin J Am Soc Nephrol 2007, 2:879-890. 10.2215/CJN.02740707, 17702717.
127. Houssiau FA, D' Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, Fiehn C, Garrido ER, Gilboe I-M, Tektonidou M, Blockmans D, Ravelingien I, Guern V, Depresseux G, Guillevin L, Ricard Cervera R, . the MAINTAIN Nephritis Trial Group Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010, 69:2083-2089. 10.1136/ard.2010.131995, 3002764, 20833738, the MAINTAIN Nephritis Trial Group.
128. Roman MJ, Shanker BA, Davis A. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosis. N Engl J Med 2003, 349:2399-2406. 10.1056/NEJMoa035471, 14681505.
129. Bruce IN, Urowitz MB, Gladman DD. Risk factors for coronary heart disease in women with systemic lupus erythematosis: the Toronto Risk Factor Study. Arthritis Rheum 2003, 48:3159-3167. 10.1002/art.11296, 14613278.
130. Houssiau FA, Lefevre C, Depresseaux G, Lambert M, Devogelaer JP, Nagant de Deuxchaisnes. Trabecular and cortical bone loss in systemic lupus erythematosis. Br J Rheum 1996, 35:244-247.
131. Jones DS, Barstad PA, Field MJ, Hachmann JP, Hayag MS, Hill KW, Iverson GM, Livingston DA, Palanki MS. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakisoligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis. J Med Chem 1995, 38:2138-2144. 10.1021/jm00012a013, 7783145.
132. Alarcon-Segovia D, Tumlin JA, Furie RA. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosis: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003, 48:442-454. 10.1002/art.10763, 12571854.
133. Sfikakis PP, Boletis JN, Lionaki S. Remission of proliferative lupus nephritis following B call depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005, 52:501-513. 10.1002/art.20858, 15693003.
134. Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006, 8:R74. 10.1186/ar1942, 1526638, 16630358.
135. Wallace DJ, Stohl W, Furie RA, Lisse JR, Mckay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, Mccune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178. 10.1002/art.24699, 2758229, 19714604.
136. Austin HA III, Boumpas DT, Vaughan EM. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994, 45:544-550. 10.1038/ki.1994.70, 8164443.
137. Barr RG, Seliger S, Appel GB. Prognosis in proliferative status and race/ethnicity. Nephrol Dial Transplant 2003, 18:2039-2046. 10.1093/ndt/gfg345, 13679478.
138. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, Wong RWS, Au TK. Longterm outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006, 119:355e25-355e33.
139. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosis. Clin Rev Allergy Immunol 2005, 29:219-228. 10.1385/CRIAI:29:3:219, 16391397.
140. Boletis JN, Loannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with clyclophosphamide for proliferative lupus nephritis. Lancet 1999, 354:569-570. 10.1016/S0140-6736(99)01575-5, 10470708.
141. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, Szeto CC, Lui SF. Longterm treatment of lupus nephritis with cyclosporin A. QJM 1998, 91:573-580. 10.1093/qjmed/91.8.573, 9893761.
142. Dostal C, Tesar V, Rychlik I, Zabka J, Vencovsky J, Bartunkova J, Stejskalova A, Tegzova D. Effect of 1 year of cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosis: a pilot study. Lupus 1998, 7:29-36.
143. Jayne D, Passweg J, Marmont A. Autologous stem cell transplantation for systemic lupus erythematosis. Lupus 2004, 13:168-176. 10.1191/0961203304lu525oa, 15119545.